2, 4, 7-substituted-7-denitrification-2 '-deoxy-2'-fluoro arabinosyl nucleosides and nucleotide prodrugs and uses thereof

A technology of alkoxy and alkyl, applied in the field of 2,4,7 substituted-7-deaza-2′-deoxy-2′-fluoroarabinosyl nucleosides and nucleotide prodrugs and their uses , which can solve the problems of side effects, expensive interferon therapy, virus recurrence, etc.

Pending Publication Date: 2022-05-13
SOUTHERN RES INST & IP
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Plus, interferon therapy is expensive, can have serious side effects, and requires daily subcutaneous injections
Newer antiviral agents, such as lamivudine, can reduce viral load but cause an...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2, 4, 7-substituted-7-denitrification-2 '-deoxy-2'-fluoro arabinosyl nucleosides and nucleotide prodrugs and uses thereof
  • 2, 4, 7-substituted-7-denitrification-2 '-deoxy-2'-fluoro arabinosyl nucleosides and nucleotide prodrugs and uses thereof
  • 2, 4, 7-substituted-7-denitrification-2 '-deoxy-2'-fluoro arabinosyl nucleosides and nucleotide prodrugs and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example

[0490] The following examples are presented to provide one of ordinary skill in the art with a complete disclosure and description of how to make and evaluate the compounds, compositions, articles of manufacture, devices and / or methods claimed herein, and are intended purely as illustrations of the invention It is not intended to limit the scope of what the inventors believe to be their invention. Efforts have been made to ensure accuracy with respect to numbers (eg, amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric.

[0491] Examples are provided herein to illustrate the invention, and the examples should not be construed as limiting the invention in any way. Examples are provided herein to illustrate the invention, and the examples should not be construed as limiting the invention in any way.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to 2, 4, 7-substituted-7-denitrification-2 '-deoxy-2'-fluoro arabinosyl nucleosides and nucleotide prodrugs capable of inhibiting viral infections and methods of using these compounds in the treatment of viral infections, the viral infections such as human immunodeficiency virus (HIV), human papilloma virus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), varicella, infectious mononuclear hyperplasia, parotitis, measles, rubella, herpes zoster, Ebola virus, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, and the like. Parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue fever (DENV), influenza, West Nile virus (WNV), zika virus (ZIKV), 229E, NL63, OC43, HKU1, Middle East Respiratory Syndrome Coronavivirus (MERS), severely acute respiratory Syndrome Coronavivirus (SERS), and severely acute respiratory Syndrome Coronavivirus (SERS) This abstract is intended as a scanning tool for search purposes in the particular art and is not intended as a limitation on the present invention.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Application No. 62 / 861,837, filed June 14, 2019, the contents of which are hereby incorporated by reference in their entirety. Background technique [0003] Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. Hepatitis B can cause both acute and chronic infections. Many people have no symptoms during the initial infection. Some people have a rapid onset with vomiting, yellowing of the skin, tiredness, dark urine, and abdominal pain. Typically, these symptoms persist for several weeks, and the initial infection rarely results in death. It can take 30 to 180 days for symptoms to start. Ninety percent of those infected around birth develop chronic hepatitis B, compared with less than 10 percent of those infected after the age of five. Most people with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7052C07H19/14
CPCC07H19/14Y02A50/30A61P31/12A61K45/06A61K31/7064
Inventor O·穆哈-查菲克L·D·布拉顿C·E·奥盖利-萨夫兰M·J·苏托
Owner SOUTHERN RES INST & IP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap